Additionally, FXYD6 expression was generally negatively correlated with many classic inhibitory immune checkpoints, which suggested down‐regulation of FXYD6 might be involved in the inhibition of immune response to glioma cells. This evidence concerns the gene FXYD6 and central nervous system cancer.